echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Blood: Brentuximab vedotin combined with chemotherapy in the treatment of ALK+ anaplastic large cell lymphoma

    Blood: Brentuximab vedotin combined with chemotherapy in the treatment of ALK+ anaplastic large cell lymphoma

    • Last Update: 2021-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Approximately 30% of pediatric patients with anaplastic large cell lymphoma (ALCL) will relapse


    Lymphoma in children

    From 2013 to 2017, the trial enrolled 68 children with ALK+ALCL, all of whom were treated with Bentuximab


    Of the 67 children who could be assessed for toxicity, 66 had completed 6 courses of chemotherapy, for a total of 399 courses that could be assessed


    EFS and OS

    EFS and OS

    The 2-year event-free survival rate (EFS) was 79.


    The 2-year event-free survival rate (EFS) was 79.


    EFS and OS of children with positive (+) or negative (-) NPM-ALK at baseline

    EFS and OS of children with positive (+) or negative (-) NPM-ALK at baseline

    The quantitative reverse transcription polymerase chain reaction of baseline NPM-ALK suggests that NPM-ALK has a certain predictive value for EFS (p=0.


    The quantitative reverse transcription polymerase chain reaction of baseline NPM-ALK suggests that NPM-ALK has a certain predictive value for EFS (p=0.


    Adding Bentuximab to standard chemotherapy does not increase the obvious toxicity or change the required treatment interval, and can prevent recurrence during treatment.


    Original source:

    Eric J.


    Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK + ALCL: results of COG trial ANHL12P1

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.